Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04539938 · ClinicalTrials.gov registry record · Phase 2
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
A Phase 2 study, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT04539938 is a Phase 2 study that has completed, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 70 participants.
The verdict
NCT04539938, a Phase 2 study, has completed, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer. Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and T-DXd.
Interventions
- DRUG tucatinib
- DRUG trastuzumab deruxtecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2025-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04539938
The ClinicalTrials.gov registry entry for NCT04539938 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tucatinib is the first listed.
NCT04539938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04539938 about?
NCT04539938 is a clinical study titled "A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer". This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer. Participants in this trial have HER2-positive (HER2+...
What is the current status of trial NCT04539938?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2020-12-01. Estimated completion is 2025-03-07.
What interventions are being tested in trial NCT04539938?
The interventions under investigation include: tucatinib (DRUG), trastuzumab deruxtecan (DRUG).
Who is sponsoring clinical trial NCT04539938?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.